Published in Cancer Microenviron on December 03, 2011
Phase 2 Study of AMG 785 in Postmenopausal Women With Low Bone Mineral Density | NCT00896532
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma | NCT01302886
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | NCT00983346
Velcade Consolidation Bone Study | NCT01286077
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | NCT01062230
Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood (2014) 0.93
Wnt and Wnt inhibitors in bone metastasis. Bonekey Rep (2012) 0.87
Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast Cancer Res (2014) 0.82
Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World J Stem Cells (2014) 0.81
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res (2016) 0.79
Adipose, Bone, and Myeloma: Contributions from the Microenvironment. Calcif Tissue Int (2016) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell (2002) 15.20
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 11.64
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Skeletal complications of malignancy. Cancer (1997) 5.41
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A (2005) 4.48
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab (2006) 4.33
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J (2003) 4.32
Retracted A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol (2007) 3.97
Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem (2005) 3.97
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med (1996) 3.41
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res (2011) 3.25
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Regulation of osteoblast differentiation by transcription factors. J Cell Biochem (2006) 2.86
TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J (2001) 2.81
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Different phenotypes for mice deficient in either activins or activin receptor type II. Nature (1995) 2.62
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer (2007) 2.55
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res (2010) 2.52
Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res (2009) 2.41
Buried alive: how osteoblasts become osteocytes. Dev Dyn (2006) 2.23
Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene (2003) 2.22
CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood (2012) 2.18
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol (2009) 2.12
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica (2006) 2.11
BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem (2003) 2.01
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood (2001) 1.93
Critical molecular switches involved in BMP-2-induced osteogenic differentiation of mesenchymal cells. Gene (2005) 1.91
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood (2005) 1.85
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest (2008) 1.81
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A (2007) 1.77
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood (2006) 1.77
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood (2007) 1.75
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood (2007) 1.75
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res (2009) 1.72
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood (2004) 1.70
Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol (2008) 1.63
A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood (2005) 1.60
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One (2008) 1.60
Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood (2001) 1.60
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood (2005) 1.59
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood (2003) 1.56
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol (2006) 1.56
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol (2005) 1.56
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood (2002) 1.47
Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide. Leuk Res (2009) 1.46
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A (2010) 1.44
A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci U S A (2008) 1.42
Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol (1992) 1.39
Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res (2009) 1.36
Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest (2001) 1.35
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood (2005) 1.35
Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol (1989) 1.33
HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood (2007) 1.32
Bortezomib inhibits human osteoclastogenesis. Leukemia (2007) 1.30
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood (2003) 1.29
Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol (2004) 1.27
Postnatally induced inactivation of Osterix in osteoblasts results in the reduction of bone formation and maintenance. Bone (2009) 1.23
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood (2007) 1.21
Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res (2009) 1.21
Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem (2000) 1.20
Role of decorin in the antimyeloma effects of osteoblasts. Blood (2008) 1.19
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol (2007) 1.19
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res (2007) 1.18
Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res (2010) 1.18
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia (2011) 1.16
Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun (2000) 1.16
Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis (2006) 1.16
Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol (2003) 1.15
Quantitative histology of myeloma-induced bone changes. Br J Haematol (1982) 1.15
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One (2010) 1.11
Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling. Am J Pathol (2008) 1.09
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res (2010) 1.09
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol (2010) 1.09
Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw (1999) 1.08
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood (2009) 1.08
BMP signals regulate Dlx5 during early avian skull development. Dev Biol (2003) 1.04
Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol (2003) 1.02
Regulation of cellular and system function by activin. Biochem Pharmacol (1998) 1.01
Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J (2011) 0.99
Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways. Mol Cell Biochem (2007) 0.99
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol (2011) 0.99
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica (2010) 0.94
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res (2009) 0.94
Evidence for the participation of endogenous activin A/erythroid differentiation factor in the regulation of erythropoiesis. Proc Natl Acad Sci U S A (1992) 0.93
New potential targets for treating myeloma bone disease. Clin Cancer Res (2006) 0.89
Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One (2010) 0.89
Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. Exp Hematol (2009) 0.88
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood (2006) 0.81
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol (2012) 2.25
Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg (2007) 2.18
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood (2010) 2.08
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood (2014) 2.01
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol (2005) 1.99
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res (2011) 1.85
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest (2008) 1.81
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res (2013) 1.75
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res (2006) 1.75
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell (2009) 1.73
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res (2006) 1.72
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood (2010) 1.66
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res (2006) 1.62
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther (2010) 1.58
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood (2006) 1.56
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood (2004) 1.46
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood (2013) 1.44
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A (2010) 1.44
NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw (2009) 1.44
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood (2009) 1.41
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol (2007) 1.41
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene (2004) 1.38
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther (2007) 1.36
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res (2007) 1.30
Multiple myeloma. J Natl Compr Canc Netw (2011) 1.28
Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma (2008) 1.26
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood (2010) 1.25
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res (2005) 1.25
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood (2005) 1.23
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood (2007) 1.21
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood (2009) 1.21
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol (2013) 1.19
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood (2010) 1.18
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol (2011) 1.14
Multiple myeloma, version 1.2013. J Natl Compr Canc Netw (2013) 1.14
Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther (2012) 1.13
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res (2007) 1.13
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol (2010) 1.11
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood (2003) 1.04
Neurological manifestations of Waldenström macroglobulinemia. Nat Clin Pract Neurol (2008) 1.01
Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw (2011) 0.98
Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. Clin Cancer Res (2014) 0.97
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene (2005) 0.97
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol (2008) 0.96
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol (2007) 0.95
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood (2005) 0.95
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res (2009) 0.94
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone (2013) 0.94
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood (2011) 0.94
Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw (2009) 0.93
Management of bone disease in multiple myeloma. Expert Rev Hematol (2014) 0.93
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res (2011) 0.93
Novel therapeutic targets for multiple myeloma. Future Oncol (2010) 0.91
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene (2005) 0.91
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw (2012) 0.89
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br J Haematol (2011) 0.89
Novel bone-targeted strategies in oncology. Clin Cancer Res (2010) 0.88
Role of decorin in multiple myeloma (MM) bone marrow microenvironment. J Bone Miner Res (2015) 0.86
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag (2008) 0.86
Retracted Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol (2008) 0.85
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. Br J Haematol (2015) 0.83
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. Br J Haematol (2006) 0.82
Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw (2015) 0.81
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. Blood (2002) 0.81
Future novel single agent and combination therapies. Cancer J (2009) 0.80
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist (2011) 0.78
The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis (2010) 0.78
Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates. Crit Rev Oncol Hematol (2011) 0.77
Inhibition of the TGF-beta signaling pathway in tumor cells. Recent Results Cancer Res (2007) 0.77
Bisphosphonates and atypical femoral fractures. N Engl J Med (2010) 0.75
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol (2011) 0.75
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc (2010) 0.75
Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. J Clin Invest (2016) 0.75
Case 27-2001: Waldenstrom's macroglobulinemia. N Engl J Med (2002) 0.75
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma. Clin Lymphoma Myeloma Leuk (2011) 0.75
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol (2006) 0.75
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.75
Clinical trials of bisphosphonates in multiple myeloma. Clin Adv Hematol Oncol (2012) 0.75
Monitoring protein synthesis in single live cancer cells. Integr Biol (Camb) (2016) 0.75